Vial develops AI-designed therapeutics and runs automated clinical trials, enabling drug programs to move from molecular design to human evaluation with unprecedented speed and precision.

Vial integrates AI-driven molecule design, automated wet labs, and high-throughput clinical operations into a single highly scalable system. This allows parallelized development, faster iteration cycles, and dramatically reduced operational overhead.

We are initially focused on Obesity, Oncology, Inflammation, and Neurological Diseases, supporting next-generation small molecule, antibody, and RNA therapeutics.

AI models are critical to design and optimize drugs and accelerate processes to bring new drugs from design into clinical trials in less than a year.

Automated labs are robotics and automated standardized workflows to produce, characterize, and test therapeutic candidates with consistent, reproducible throughput at large scale.

Automated clinical trials move AI-designed drugs directly into real-world evaluation using Vial’s high-throughput technology platform. Automation reduces manual data entry, increases protocol compliance, and accelerates readouts.

Thanks to fully integrated AI design, automated labs, and clinical automation, programs can progress from concept to clinical evaluation significantly faster than traditional approaches. Specific timelines depend on modality and regulatory requirements.

All lab and clinical systems are built to meet rigorous regulatory standards, with automated audit trails, reproducible workflows, and real-time quality monitoring across the entire development lifecycle.